nach oben

Neurotherapeutics

Erschienen in:

01.04.2011 | Review

Latest Approaches for the Treatment of Spasticity and Autonomic Dysreflexia in Chronic Spinal Cord Injury

verfasst von: Alexander G. Rabchevsky, Patrick H. Kitzman

Erschienen in: Neurotherapeutics | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Summary

Two of the most prevalent secondary complications following spinal cord injury (SCI), besides loss of function and/or sensation below the level of injury, are uncontrolled muscle spasticity and hypertensive autonomic dysreflexia. Despite the desires of the SCI community, there have been few advances in the treatment and/or management of these fundamental impediments to the quality of life associated with chronic SCI. Therefore, the purpose of this review is to focus on current drug treatment strategies that alleviate symptoms of spasticity and autonomic dysfunction. Subsequently, looking ahead, we discuss whether individuals suffering from autonomic dysreflexia and/or muscle spasms can take certain compounds that specifically and rapidly block the neurotransmission of pain into the injured spinal cord to get rapid relief for both aberrant reflexes for which painful stimuli below the level of SCI are common precipitants.

Nur mit Berechtigung zugänglich

Anderson KD. Targeting recovery: priorities of the spinal cord-injured population. J Neurotrauma 2004;21:1371–1383.PubMedCrossRef

Kitzman P. Changes in vesicular glutamate transporter 2, vesicular GABA transporter and vesicular acetylcholine transporter labeling of sacrocaudal motoneurons in the spastic rat. Exp Neurol 2006;197:407–419.PubMedCrossRef

Karlsson AK. Autonomic dysreflexia. Spinal Cord 1999;37:383–391.PubMedCrossRef

Rabchevsky AG. Segmental organization of spinal reflexes mediating autonomic dysreflexia after spinal cord injury. Prog Brain Res 2006;152:265–274.PubMedCrossRef

Kewalramani LS. Autonomic dysreflexia in traumatic myelopathy. Am J Phys Med 1980;59:1–21.PubMed

Harati Y. Autonomic disorders associated with spinal cord injury. In: Low PA, ed. Clinical autonomic disorders, 2nd edit. Philadelphia: Lippincott-Raven; 1997, 455–461.

Krassioukov AV, Furlan JC, Fehlings MG. Autonomic dysreflexia in acute spinal cord injury: an under-recognized clinical entity. J Neurotrauma 2003;20:707–716.PubMedCrossRef

Snow JC, Sideropoulos HP, Kripke BJ, Freed MM, Shah NK, Schlesinger RM. Autonomic hyperreflexia during cystoscopy in patients with high spinal cord injuries. Paraplegia 1978;15:327–332.PubMedCrossRef

Blackmer J. Rehabilitation medicine: 1. Autonomic dysreflexia. CMAJ 2003;169:931–935.PubMed

10.

Pathak MS, Nguyen HT, Graham HK, Moore AP. Management of spasticity in adults: practical application of botulinum toxin. Eur J Neurol 2006;13(suppl 1):42–50.PubMedCrossRef

11.

Simon O, Yelnik AP. Managing spasticity with drugs. Eur J Phys Rehabil Med 2010;46:401–410.PubMed

12.

Young RR. Baclofen. Arch Neurol 1977;34:722.

13.

Young RR, Delwaide PJ. Drug therapy: spasticity (second of two parts). N Engl J Med 1981;304:96–99.PubMedCrossRef

14.

Yang K, Feng Y, Li Y. Baclofen inhibition of dorsal root-evoked inhibitory postsynaptic currents in substantia gelatinosa neurons of rat spinal cord slice. Brain Res 2001;900:320–323.PubMedCrossRef

15.

Abbruzzese G. The medical management of spasticity. Eur J Neurol 2002;(9 suppl 1):30–34; discussion 53–61.

16.

Elovic E. Principles of pharmaceutical management of spastic hypertonia. Phys Med Rehabil Clin N Am 2001;12:793–816, vii.

17.

Jamous A, Kennedy P, Psychol C, Grey N. Psychological and emotional effects of the use of oral baclofen: a preliminary study. Paraplegia 1994;32:349–353.PubMedCrossRef

18.

Kirshblum S. Treatment alternatives for spinal cord injury related spasticity. J Spinal Cord Med 1999;22:199–217.PubMed

19.

Taricco M, Adone R, Pagliacci C, Telaro E. Pharmacological interventions for spasticity following spinal cord injury. Cochrane Database Syst Rev 2000; Issue 2. Art. No.: CD001131. doi:10.1002/14651858.CD001131.

20.

Burns AS, Meythaler JM. Intrathecal baclofen in tetraplegia of spinal origin: efficacy for upper extremity hypertonia. Spinal Cord 2001;39:413–419.PubMedCrossRef

21.

Coffey JR, Cahill D, Steers W, et al. Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J Neurosurg 1993;78:226–232.PubMedCrossRef

22.

Ivanhoe CB, Tilton AH, Francisco GE. Intrathecal baclofen therapy for spastic hypertonia. Phys Med Rehabil Clin N Am 2001;12:923–938, viii-ix.

23.

Zahavi A, Geertzen JH, Middel B, Staal M, Rietman JS. Long term effect (more than five years) of intrathecal baclofen on impairment, disability, and quality of life in patients with severe spasticity of spinal origin. J Neurol Neurosurg Psychiatry 2004;75:1553–1557.PubMedCrossRef

24.

Yelnik AP, Simon O, Bensmail D, et al. Drug treatments for spasticity. Ann Phys Rehabil Med 2009;52:746–756.PubMed

25.

Soni BM, Mani RM, Oo T, Vaidyanathan S. Treatment of spasticity in a spinal cord-injured patient with intrathecal morphine due to intrathecal baclofen tolerance--a case report and review of literature. Spinal Cord 2003;41:586–589.PubMedCrossRef

26.

Coffey RJ, Edgar TS, Francisco GE, et al. Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome. Arch Phys Med Rehabil 2002;83:735–741.PubMedCrossRef

27.

Palmeri A, Wiesendanger M. Concomitant depression of locus coeruleus neurons and of flexor reflexes by an alpha 2-adrenergic agonist in rats: a possible mechanism for an alpha 2-mediated muscle relaxation. Neuroscience 1990;34:177–187.PubMedCrossRef

28.

Wagstaff AJ, Bryson HM. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs 1997;53:435–452.PubMedCrossRef

29.

Burchiel KJ, Hsu FP. Pain and spasticity after spinal cord injury: mechanisms and treatment. Spine (Phila Pa 1976) 2001;26(24 suppl):S146–S160.

30.

Kita M, Goodkin DE. Drugs used to treat spasticity. Drugs 2000;59:487–495.PubMedCrossRef

31.

Mirbagheri MM, Chen D, Rymer WZ. Quantification of the effects of an alpha-2 adrenergic agonist on reflex properties in spinal cord injury using a system identification technique. J Neuroeng Rehabil 2010;7:29.PubMedCrossRef

32.

Dolly JO, Aoki KR. The structure and mode of action of different botulinum toxins. Eur J Neurol 2006;13(suppl 4):1–9.PubMedCrossRef

33.

Dong M, Yeh F, Tepp WH, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006;312:592–596.PubMedCrossRef

34.

Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache 2003;43(suppl 1):S16–24.PubMedCrossRef

35.

Pellizzari R, Rossetto O, Schiavo G, Montecucco C. Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philos Trans R Soc Lond B Biol Sci 1999;354:259–268.PubMedCrossRef

36.

Aoki KR. Pharmacology and immunology of botulinum toxin serotypes. J Neurol. 2001;248(suppl 1):3–10.PubMedCrossRef

37.

Crawford P, Ghadiali E, Lane R, Blumhardt L, Chadwick D. Gabapentin as an antiepileptic drug in man. J Neurol Neurosurg Psychiatry 1987;50:682–686.PubMedCrossRef

38.

Levendoglu F, Ogun CO, Ozerbil O, Ogun TC, Ugurlu H. Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury. Spine (Phila Pa 1976). 2004;29:743–751.

39.

Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999;159:1931–1937.PubMedCrossRef

40.

Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998;280:1837–1842.PubMedCrossRef

41.

Wheeler G. Gabapentin. Pfizer. Curr Opin Investig Drugs 2002;3:470–477.PubMed

42.

Coderre TJ, Kumar N, Lefebvre CD, Yu JS. Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate. J Neurochem 2005;94:1131–1139.PubMedCrossRef

43.

Coderre TJ, Kumar N, Lefebvre CD, Yu JS. A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. J Neurochem 2007;100:1289–1299.PubMedCrossRef

44.

Maneuf YP, Blake R, Andrews NA, McKnight AT. Reduction by gabapentin of K+-evoked release of [3H]-glutamate from the caudal trigeminal nucleus of the streptozotocin-treated rat. Br J Pharmacol 2004;141:574–579.PubMedCrossRef

45.

Maneuf YP, McKnight AT. Block by gabapentin of the facilitation of glutamate release from rat trigeminal nucleus following activation of protein kinase C or adenylyl cyclase. Br J Pharmacol 2001;134:237–240.PubMedCrossRef

46.

Shimoyama M, Shimoyama N, Hori Y. Gabapentin affects glutamatergic excitatory neurotransmission in the rat dorsal horn. Pain 2000;85:405–414.PubMedCrossRef

47.

Tran-Van-Minh A, Dolphin AC. The alpha2delta ligand gabapentin inhibits the Rab11-dependent recycling of the calcium channel subunit alpha2delta-2. J Neurosci. 2010;30:12856–12867.PubMedCrossRef

48.

Gruenthal M, Mueller M, Olson WL, Priebe MM, Sherwood AM, Olson WH. Gabapentin for the treatment of spasticity in patients with spinal cord injury. Spinal Cord 1997;35:686–689.PubMedCrossRef

49.

Priebe MM, Sherwood AM, Graves DE, Mueller M, Olson WH. Effectiveness of gabapentin in controlling spasticity: a quantitative study. Spinal Cord 1997;35:171–175.PubMedCrossRef

50.

French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003;60:1631–1637.PubMed

51.

Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004;110:628–638.PubMedCrossRef

52.

Fink K, Dooley DJ, Meder WP, et al. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology. 2002;42:229–236.PubMedCrossRef

53.

Bryans JS, Wustrow DJ. 3-substituted GABA analogs with central nervous system activity: a review. Med Res Rev 1999;19:149–177.PubMedCrossRef

54.

Bradley LJ, Kirker SG. Pregabalin in the treatment of spasticity: a retrospective case series. Disabil Rehabil 2008;30:1230–1232.PubMedCrossRef

55.

Costa E, Guidotti A. Molecular mechanisms in the receptor action of benzodiazepines. Annu Rev Pharmacol Toxicol 1979;19:531–545.PubMedCrossRef

56.

Nance PW, Shears AH, Nance DM. Clonidine in spinal cord injury. Can Med Assoc J 1985;133:41–42.PubMed

57.

Nance PW, Shears AH, Nance DM. Reflex changes induced by clonidine in spinal cord injured patients. Paraplegia 1989;27:296–301.PubMedCrossRef

58.

Ellis KO, Carpenter JF. Mechanism of control of skeletal-muscle contraction by dantrolene sodium. Arch Phys Med Rehabil 1974;55:362–369.PubMed

59.

Herman R, Mayer N, Mecomber SA. Clinical pharmaco--physiology of dantrolene sodium. Am J Phys Med 1972;51:296–311.PubMed

60.

Weiser R, Terenty T, Hudgson P, Weightman D. Dantrolene sodium in the treatment of spasticity in chronic spinal cord disease. Practitioner 1978;221:123–127.PubMed

61.

Stevenson VL. Rehabilitation in practice: spasticity management. Clin Rehabil 2010;24:293–304.PubMedCrossRef

62.

Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003;42:327–360.PubMedCrossRef

63.

Pryce G, Baker D. Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br J Pharmacol 2007;150:519–525.PubMedCrossRef

64.

Lakhan SE, Rowland M. Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. BMC Neurol 2009;9:59.PubMedCrossRef

65.

Hagenbach U, Luz S, Ghafoor N, et al. The treatment of spasticity with Delta9-tetrahydrocannabinol in persons with spinal cord injury. Spinal Cord 2007;45:551–562.PubMedCrossRef

66.

Smith PF. New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids. Ther Clin Risk Manag 2010;6:59–63.PubMedCrossRef

67.

Krassioukov AV, Weaver LC. Episodic hypertension due to autonomic dysreflexia in acute and chronic spinal cord-injured rats. Am J Physiol 1995;268(5 Pt 2):H2077–H2083.PubMed

68.

Rivas DA, Chancellor MB, Huang B, Salzman SK. Autonomic dysreflexia in a rat model spinal cord injury and the effect of pharmacologic agents. Neurourol Urodyn 1995;14:141–152.PubMedCrossRef

69.

Maiorov DN, Fehlings MG, Krassioukov AV. Relationship between severity of spinal cord injury and abnormalities in neurogenic cardiovascular control in conscious rats. J Neurotrauma. 1998;15:365–374.PubMedCrossRef

70.

Maiorov DN, Weaver LC, Krassioukov AV. Relationship between sympathetic activity and arterial pressure in conscious spinal rats. Am J Physiol 1997;272(2 Pt 2):H625–H631.PubMed

71.

Hou S, Duale H, Cameron AA, Abshire SM, Lyttle TS, Rabchevsky AG. Plasticity of lumbosacral propriospinal neurons is associated with the development of autonomic dysreflexia after thoracic spinal cord transection. J Comp Neurol 2008;509:382–399.PubMedCrossRef

72.

Krassioukov AV, Weaver LC. Morphological changes in sympathetic preganglionic neurons after spinal cord injury in rats. Neuroscience 1996;70:211–225.PubMedCrossRef

73.

Krenz NR, Weaver LC. Sprouting of primary afferent fibers after spinal cord transection in the rat. Neuroscience 1998;85:443–458.PubMedCrossRef

74.

Krenz NR, Weaver LC. Changes in the morphology of sympathetic preganglionic neurons parallel the development of autonomic dysreflexia after spinal cord injury in rats. Neuroscience letters. 1998;243:61–64.PubMedCrossRef

75.

Chau D, Johns DG, Schramm LP. Ongoing and stimulus-evoked activity of sympathetically correlated neurons in the intermediate zone and dorsal horn of acutely spinalized rats. Journal of neurophysiology 2000;83:2699–2707.PubMed

76.

Stjernberg L. Cutaneous vasomotor sensitivity to noradrenalin in spinal and intact man. Scand J Rehabil Med 1986;18:127–132.PubMed

77.

Maiorov DN, Krenz NR, Krassioukov AV, Weaver LC. Role of spinal NMDA and AMPA receptors in episodic hypertension in conscious spinal rats. Am J Physiol 1997;273(3 Pt 2):H1266–H1274.PubMed

78.

Cameron AA, Smith GM, Randall DC, Brown DR, Rabchevsky AG. Genetic manipulation of intraspinal plasticity after spinal cord injury alters the severity of autonomic dysreflexia. J Neurosci 2006;26:2923–2932.PubMedCrossRef

79.

Krenz NR, Meakin SO, Krassioukov AV, Weaver LC. Neutralizing intraspinal nerve growth factor blocks autonomic dysreflexia caused by spinal cord injury. J Neurosci 1999;19:7405–7414.PubMed

80.

Marsh DR, Wong ST, Meakin SO, MacDonald JI, Hamilton EF, Weaver LC. Neutralizing intraspinal nerve growth factor with a trkA-IgG fusion protein blocks the development of autonomic dysreflexia in a clip-compression model of spinal cord injury. J Neurotrauma 2002;19:1531–1541.PubMedCrossRef

81.

Medicine CfSC. Acute management of autonomic dysreflexia: individuals with spinal cord injury presenting to health-care facilities. J Spinal Cord Med 2002;25(suppl 1):S67–S88.

82.

Torfgard KE, Ahlner J. Mechanisms of action of nitrates. Cardiovasc Drugs Ther 1994;8:701–717.PubMedCrossRef

83.

Lee BY, Karmakar MG, Herz BL, Sturgill RA. Autonomic dysreflexia revisited. J Spinal Cord Med 1995;18:75–87.PubMed

84.

Thyberg M, Ertzgaard P, Gylling M, Granerus G. Effect of nifedipine on cystometry-induced elevation of blood pressure in patients with a reflex urinary bladder after a high level spinal cord injury. Paraplegia 1994;32:308–313.PubMedCrossRef

85.

Braddom RL, Rocco JF. Autonomic dysreflexia. A survey of current treatment. Am J Phys Med Rehabil 1991;70:234–241.PubMedCrossRef

86.

Chancellor MB, Erhard MJ, Hirsch IH, Stass WE, Jr. Prospective evaluation of terazosin for the treatment of autonomic dysreflexia. J Urol 1994;151:111–113.PubMed

87.

Vaidyanathan S, Soni BM, Sett P, Watt JW, Oo T, Bingley J. Pathophysiology of autonomic dysreflexia: long-term treatment with terazosin in adult and paediatric spinal cord injury patients manifesting recurrent dysreflexic episodes. Spinal Cord 1998;36:761–770.PubMedCrossRef

88.

Krum H, Louis WJ, Brown DJ, Howes LG. A study of the alpha-1 adrenoceptor blocker prazosin in the prophylactic management of autonomic dysreflexia in high spinal cord injury patients. Clin Auton Res 1992;2:83–88.PubMedCrossRef

89.

Santajuliana D, Zukowska-Grojec Z, Osborn JW. Contribution of alpha- and beta- adrenoceptors and neuropeptide-Y to autonomic dysreflexia. Clin Auton Res 1995;5:91–97.PubMedCrossRef

90.

Landrum LM, Thompson GM, Blair RW. Does postsynaptic alpha 1-adrenergic receptor supersensitivity contribute to autonomic dysreflexia? Am J Physiol 1998;274(4 Pt 2):H1090–H1098.PubMed

91.

Khastgir J, Drake MJ, Abrams P. Recognition and effective management of autonomic dysreflexia in spinal cord injuries. Expert Opin Pharmacother 2007;8:945–956.PubMedCrossRef

92.

McMahon D, Tutt M, Cook AM. Pharmacological management of hemodynamic complications following spinal cord injury. Orthopedics 2009;32:331.PubMedCrossRef

93.

Naftchi NE, Richardson JS. Autonomic dysreflexia: pharmacological management of hypertensive crises in spinal cord injured patients. J Spinal Cord Med 1997;20:355–360.PubMed

94.

Popa C, Popa F, Grigorean VT, et al. Vascular dysfunctions following spinal cord injury. J Med Life 2010;3:275–285.PubMed

95.

Kitzman P. VGLUT1 and GLYT2 labeling of sacrocaudal motoneurons in the spinal cord injured spastic rat. Exp Neurol 2007;204:195–204.PubMedCrossRef

96.

Kitzman PH, Uhl TL, Dwyer MK. Gabapentin suppresses spasticity in the spinal cord-injured rat. Neuroscience 2007;149:813–821.PubMedCrossRef

97.

Rabchevsky AG, Patel SP, Duale H, Lyttle TS, O’Dell CR, Kitzman PH. Gabapentin for spasticity & autonomic dysreflexia after severe spinal cord injury. Spinal Cord 2011;49:99–105.

98.

Rabchevsky AG, Patel SP, Lyttle TS, O’Dell CR, Kitzman PH. Effects of chronic versus acute gabapentin administration on spasticity & autonomic dysreflexia after severe spinal cord injury. J Neurotrauma 2010;26:A–73. Abstract.

Titel: Latest Approaches for the Treatment of Spasticity and Autonomic Dysreflexia in Chronic Spinal Cord Injury
verfasst von: Alexander G. Rabchevsky
Patrick H. Kitzman
Publikationsdatum: 01.04.2011
Verlag: Springer-Verlag
Erschienen in: Neurotherapeutics / Ausgabe 2/2011
Print ISSN: 1933-7213
Elektronische ISSN: 1878-7479
DOI: https://doi.org/10.1007/s13311-011-0025-5

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2011

Inhibition of Cysteine Proteases in Acute and Chronic Spinal Cord Injury

Oligodendrocyte Fate after Spinal Cord Injury

Hypothermic Treatment for Acute Spinal Cord Injury

Targeting Mitochondrial Function for the Treatment of Acute Spinal Cord Injury

Role of Matrix Metalloproteinases and Therapeutic Benefits of Their Inhibition in Spinal Cord Injury